CD59: a promising target for tumor immunotherapy

Future Oncol. 2018 Apr;14(8):781-791. doi: 10.2217/fon-2017-0498. Epub 2018 Mar 9.

Abstract

CD59 has been identified as a glycosylphosphatidylinositol-anchored membrane protein that acts as an inhibitor of the formation of the membrane attack complex to regulate complement activation. Recent studies have shown that CD59 is highly expressed in several cancer cell lines and tumor tissues. CD59 also regulates the function, infiltration and phenotypes of a variety of immune cells in the tumor microenvironment. Herein, we summarized recent advances related to the functions and mechanisms of CD59 in the tumor microenvironment. Therapeutic strategies that seek to modulate the functions of CD59 in the tumor microenvironment could be a promising direction for tumor immunotherapy.

Keywords: CD59; complement; immunotherapy; microenvironment; tumor.

Publication types

  • Review

MeSH terms

  • CD59 Antigens / antagonists & inhibitors
  • CD59 Antigens / genetics*
  • CD59 Antigens / immunology
  • Humans
  • Immunotherapy*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Tumor Microenvironment / genetics
  • Tumor Microenvironment / immunology

Substances

  • CD59 Antigens